Search for: "BRISTOL-MYERS SQUIBB"
Results 681 - 700
of 866
Sort by Relevance
|
Sort by Date
7 Dec 2009, 2:12 am
Most notably, the parties to the Bristol- Myers Squibb securities class action lawsuit agreed to settle that case for $300 million while the case was on appeal to the Third Circuit following the district court’s dismissal. [read post]
3 Dec 2009, 10:16 pm
Supporters can click the Make it Happen link and send an email to the CEOs of Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Pfizer Inc. and Sequoia Pharmaceuticals Inc. [read post]
24 Nov 2009, 1:11 am
Other defendants named in the MDL include Bristol-Myers Squibb Co., Solvay Pharmaceuticals Inc., Watson Pharmaceuticals Inc. and Ortho-McNeil Janssen Pharmaceuticals Inc. [read post]
24 Nov 2009, 1:11 am
Other defendants named in the MDL include Bristol-Myers Squibb Co., Solvay Pharmaceuticals Inc., Watson Pharmaceuticals Inc. and Ortho-McNeil Janssen Pharmaceuticals Inc. [read post]
16 Nov 2009, 2:17 am
Bristol-Myers Squibb is splitting off its holdings in infant formula maker Mead Johnson Nutrition in order to focus on its biopharmaceutical business. [read post]
11 Nov 2009, 4:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://duncanbucknell.com/subscribe/ Highlights this week included: EU: Generics producers: Criminal sanctions can stop counterfeit drugs (IP Watch) Prandin (Repaglinide) – US: Federal Circuit grants stay of preliminary relief pending full appellate review: Novo Nordisk v Caraco (Patently-O) General Eduardo Pisani of Bristol-Myers Squibb is the new IFPMA… [read post]
11 Nov 2009, 4:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: EU: Generics producers: Criminal sanctions can stop counterfeit drugs (IP Watch) Prandin (Repaglinide) - US: Federal Circuit grants stay of preliminary relief pending full appellate review: Novo Nordisk v Caraco (Patently-O) General Eduardo Pisani of Bristol-Myers Squibb is the new IFPMA Director General (IP Watch) Is the… [read post]
11 Nov 2009, 4:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: EU: Generics producers: Criminal sanctions can stop counterfeit drugs (IP Watch) Prandin (Repaglinide) - US: Federal Circuit grants stay of preliminary relief pending full appellate review: Novo Nordisk v Caraco (Patently-O) General Eduardo Pisani of Bristol-Myers Squibb is the new IFPMA Director General (IP Watch) Is the… [read post]
10 Nov 2009, 2:44 am
High Court (Administrative Division) Islam v Paphos District Court of Cyprus [2009] EWHC 2786 (Admin) (06 November 2009) Bristol-Myers Squibb Pharmaceuticals Ltd, R (on the application of) v National Institute for Health and Clinical Excellence [2009] EWHC 2722 (Admin) (06 November 2009) Medical Protection Society Ltd, R (on the application of) v HM Revenue & Customs [2009] EWHC [...] [read post]
10 Nov 2009, 2:01 am
Regina (Bristol-Myers Squibb Pharmaceuticals Ltd) v National Institute for Health and Clinical Excellence [2009] EWHC 2722 (Admin); [2009] WLR (D) 318 "Art 6 of Council Directive 89/105/EEC relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems (OJ L40) ('the [...] [read post]
9 Nov 2009, 6:01 am
., Bristol-Myers Squibb Co. and four other drug companies have paid a total of $7 billion in fines and penalties. [read post]
2 Nov 2009, 1:24 pm
At the Wall Street Journal, Dow Jones Newswire’s Kristina Peterson addresses the Court’s denial of cert. in a drug-patent dispute between generic drug manufacturer Apotex Corp. and patent-holders Sanofi-Aventis and Bristol-Myers Squibb, while the Associated Press has coverage of the Court’s decision not to hear an appeal to stop the release of documents relating to sexual abuse lawsuits against Roman Catholic priests in… [read post]
28 Oct 2009, 3:54 pm
Bristol-Myers Squibb 7. [read post]
19 Oct 2009, 6:40 am
The conference will feature distinguished speakers from such companies as DuPont, Wal-Mart, American Airlines, Intel, Microsoft, Google, Bristol-Myers Squibb, NBC Universal, GE, Wyeth Pharmaceuticals, Prudential, Freddie Mac, Verizon and many others! [read post]
13 Oct 2009, 9:59 pm
As part of the effort to encourage these companies to pool their patents, MSF has launched an e-mail writing campaign calling on Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Johnson & Johnson, Gilead Sciences, GlaxoSmithKline, Merck & Co, Pfizer, and Sequoia Pharmaceuticals to place specific HIV drug patents... [read post]
9 Sep 2009, 7:14 am
– Dispute between Wyeth and Dexel (The IP Factor) EpiPen (Epinephrine) – US: King Pharmaceuticals, Meridian Medical Technology file patent infringement suit against Teva following Para IV certification (Patent Docs) Seroxat (Paroxetine) – Israel: not even sublime, just ridiculous – Israel PTO decision in Unipharm v SmithKline Beecham (America-Israel Patent Law) Stelara (Ustekinumab, anti-IL-12 antibody) – Centocor seeks review of BPAI decision… [read post]
7 Sep 2009, 12:06 pm
Eighteen months after the auction rate securities markets collapsed when Wall Street withdrew its support, companies like Bristol-Myers Squibb Co., Texas Instruments, Corning, and Teva Pharmaceuticals are still suffering from the Wall Street debacle. [read post]
28 Aug 2009, 8:11 am
(patent infringement) 8/28: Bristol-Myers Squibb Co., Bristol-Myers Squibb Pharma Co. v. [read post]
27 Aug 2009, 1:30 am
" Some examples included:$54,000 per year for Avastatin, made by Genentech,$31,000 per year for Terceva, made by Genentech, and$25,000 for Thalidomid, made by Celgene.The article shows how the prices of these drugs drastically ratcheted upwards in the 1990's, starting with Taxol, made by Bristol-Myers-Squibb, at $4,000 per year, starting in 1992, through Herceptin, made by Genentech, at $20,000 per year, in 1998, to Erbitux, at $100,000 per year, made by… [read post]
29 Jul 2009, 6:45 am
Tafas v Doll (Patent Docs) US: For stem cells, it seems that conception is enough: University of Pittsburgh v Hedrick (Patent Docs) (Patents4Life) US: General Accountability Office report on Bayh-Dole: Leverage to promote commercialisation of federally-funded inventions (PatentBIOtech) US: AlphaVax seeks review of BPAI decision awarding priority of invention to Novartis in interference between patents related to Alphavirus (Patent Docs) US: Teva, Taro lobby US legislators on biogenerics… [read post]
